Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhibitors to factor IX contain all IgG subclasses except IgG3.

K H Orstavik1

  • 1Department of Medical Genetics, Ullevål Hospital, Oslo, Norway.

Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1990
PubMed
Summary

Inhibitors in haemophilia B patients are mainly IgG4 antibodies, regardless of titre. This finding is crucial as IgG4 does not activate complement, potentially explaining inhibitor persistence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lack of association between skewing of X-chromosome inactivation in blood cells and colorectal cancer.

The International journal of biological markers·2008
Same author

X chromosome inactivation in females with multiple sclerosis.

European journal of neurology·2007
Same author

Increased skewing of X chromosome inactivation with age in both blood and buccal cells.

Cytogenetic and genome research·2007
Same author

Myopathy with skeletal asymmetry and hemidiaphragm elevation is caused by myotubularin mutations.

Neurology·2005
Same author

High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer.

Journal of medical genetics·2005
Same author

X-inactivation patterns in carriers of X-linked myotubular myopathy.

Neuromuscular disorders : NMD·2003

Area of Science:

  • Immunology
  • Hematology

Background:

  • Five percent of patients with haemophilia B develop inhibitors to factor IX.
  • Understanding the immunoglobulin subclass of these IgG inhibitors is clinically relevant.

Purpose of the Study:

  • To characterize the immunoglobulin subclass of factor IX inhibitors in haemophilia B patients.
  • To develop a sensitive method for subclass identification.

Main Methods:

  • Developed a novel method combining crossed immunoelectrophoresis and enzyme-linked immunoassay.
  • Utilized monoclonal antibodies specific to IgG subclasses for identification.

Main Results:

  • All seven inhibitors studied showed a strong reaction with IgG4 antibodies.
  • IgG1 and IgG2 were detected depending on inhibitor titre; IgG3 was undetectable.
  • IgG4 was the predominant subclass in both high and low titre inhibitors.

Conclusions:

  • Factor IX inhibitors in haemophilia B are predominantly IgG4, a non-complement-binding subclass.
  • The presence of IgG4 may contribute to the persistence of inhibitors.
  • Inhibitors are polyclonal, even in early stages of development.

Related Experiment Videos